Carregant...
The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches
Objectives: FDA has approved Onabotulinum toxin type A (BoNTA) for prophylactic treatment of chronic migraines. Recent studies have explored its potential new indications, like treating post-traumatic headaches. Patients and Methods: This is a retrospective chart review of 717 patients, who had fail...
Guardat en:
| Publicat a: | Front Neurol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6763695/ https://ncbi.nlm.nih.gov/pubmed/31616362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.01009 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|